A case of left ventricular dysfunction without myocardial inflammation caused by tislelizumab
A 59-year-old female patient with advanced lung adenocarcinoma developed acute left heart failure after one cycle of immunotherapy with tislelizumab 200 mg.The brain natriuretic peptide was significantly increased,and the myocardial enzyme spectrum remained normal.The cause may be immune-related non-myocardial inflammatory left ventricular dysfunction.After active glucocorticoid therapy,the patient's symptoms of heart failure were significantly relieved,but left ventricular dysfunction could not be reversed.Therefore,for patients with tumor immunotherapy of left ventricular function after injury,while myocardial enzyme spectrum continue to normal,still should take into account the immune correlation of the left ventricular function of myocardial inflammatory damage,need to use hormone therapy,and the left ventricular function damage is irreversible.
TirelizumabLeft ventricular dysfunction without myocardial inflammationImmune-related adverse events
万方数据
维普
